The allergist's community has recently celebrated 100 year of Allergen Immunotherapy (AIT). Unfortunately the implemention of this treatment is still impaired by some challenges http://bit.ly/2nxBNnx.
Allergen-specific immunotherapy (AIT) in its subcutaneous and sublingual forms is currently a well-established and experimentally supported treatment for respiratory allergy and hymenoptera venom allergy. The use of AIT in asthma and the application of new approaches are expanding.
There have been the following recent advances in the field of AIT:
- better understanding of molecular mechanisms of allergy
- production of well-characterized extracts
- improved diagnostic techniques
- specific products in tablet form have recently been approved in the United States
- sublingual immunotherapy has been found to be effective in asthma, which until recently had been a matter of debate
- oral and sublingual desensitization for food allergy
- new options in near future include new routes of administration (intralymphatic and epicutaneous), allergoids, engineered allergens, and peptides. The use of component-resolved diagnosis techniques will further refine and target AIT prescriptions.
AIT remains a viable treatment option, especially after the introduction of standardized tablets for some allergens. Food allergy and new administration routes represent a promising expansion.
Current insights in allergen immunotherapy http://bit.ly/2nqxYjG